Among the new drug combinations tested in mRCC, there is also the one examined in the phase Ib/II TiNivo study, which evaluated the efficacy and safety of combination therapy with nivolumab plus tivozanib, a highly potent and selective VEGFR-TKI approved by the European Medicines Agency (EMA) for first-line treatment of patients with mRCC (54), and showed a generally tolerable profile and promising anti-tumor efficacy (55). The gene discussed is KDR; the disease is neoplasm.